Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Authors:
- 23 October 2025
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 3335-3352
Abstract
Cancer is a significant health burden throughout the world. Gliomas are a type of cancer with the origin of central nervous system. They are the most prevalent group of brain malignancies. Chemotherapy is an integral component of standard treatment strategies for this disease. Carmustine is regarded as one of the most effective chemotherapy drugs against different cancer types and, most importantly, Gliomas. However development of resistance to Carmustine has restricted its application. It is evidenced that non-coding RNAs, especially microRNAs (miRNAs, miRs), play significant roles in association with the occurrence of this phenomenon. In the present systematic study, the interaction mechanisms between non-coding RNAs And Carmustine in the modulation of sensitivity to this drug in cancer have been investigated. The search and analysis steps followed PRISMA guidelines. A comprehensive search was conducted across databases including PubMed, Scopus, and Web of Science. According to the opted criteria, a total of 12 studies were eligible for inclusion in the study. Up or downregulation of non-coding RNA expression levels effectively influences the biology of various signaling pathways in Glioblastoma cell lines or tumors. Eventually, these significant influences would be translated into an altered status of sensitivity to Carmustine. A deeper understanding of the underscored network of interactions could be potentially helpful for improving the efficacy of chemotherapy-based approaches against cancer.Keywords
This publication has 121 references indexed in Scilit:
- SIRT1 as a masterful reciprocal regulator of molecular mechanisms and signaling pathways involved in tumor growth and expansionClinical and Experimental Medicine, 2025
- The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic reviewNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- MicroRNA-143 overexpression enhances the chemosensitivity of A172 glioblastoma cells to carmustineNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy2024
- Let-7a-3p overexpression increases chemosensitivity to carmustine and synergistically promotes autophagy and suppresses cell survival in U87MG glioblastoma cancer cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Dual role of sprouty2 as an inhibitor of RAS/ERK‐driven proliferation and a promoter of cancer invasion in KRAS wild‐type colorectal cancerMolecular Carcinogenesis, 2023
- Protective role of Codiaeum variegatum against genotoxicity induced by carmustine in somatic and germ cells of male miceMolecular Biology Reports, 2022
- MiRNA-21-5p Accelerates EMT and Inhibits Apoptosis of Laryngeal Carcinoma via Inhibiting KLF6 ExpressionBiochemical Genetics, 2022
- miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiformeActa Neurochirurgica, 2019
- Is there a role for IGF‐1 in the development of second primary cancers?Cancer Medicine, 2016